Michael R. Hayden - 22 Jun 2021 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role
Director
Signature
/s/ Tryn Stimart, attorney-in-fact
Issuer symbol
ABCL
Transactions as of
22 Jun 2021
Net transactions value
-$2,550,000
Form type
4
Filing time
22 Jun 2021, 18:50:49 UTC
Previous filing
03 Jun 2021
Next filing
06 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABCL Common Shares Sale $2,550,000 -100,000 -9.1% $25.50 1,003,397 22 Jun 2021 See footnote F1, F2
holding ABCL Common Shares 118,245 22 Jun 2021 By spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 22, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50.
F2 These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.